SAPHIR – Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk
Bernhard Iglseder - Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft GmbH Christian-Doppler-Klinik, Salzburg, Austria
The Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR) is a general population study based in Salzburg, Austria. Healthy unrelated subjects aged between 40 and 70 years of Caucasian origin were recruited in the greater area of the Austrian city of Salzburg. The principal aim of the study was to investigate genetic and environmental factors contributing to atherosclerotic vascular diseases. All study subjects provided informed consent, and the study protocol was approved by the local ethics committee.
A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet. 2001 Jun;28(2):178-83
Genetic Architecture of the APM1 Gene and Its Influence on Adiponectin Plasma Levels and Parameters of the Metabolic Syndrome in 1,727 Healthy Caucasians. Diabetes. 2006 Feb;55(2):375-84
Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest. 2007 Feb;37(2):109-16